COMP <GO>
ABCL vs ARQT // EV/EBITDA & P/E VALUATION
AbCellera Biologics Inc. (NASDAQ) VS. Arcutis Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ABCL 2
— ARQT 7
■ METRIC PARITY
LAST: $12.27 (-6.19%) • MKT CAP: $4.24B
valuation
—
LAST: $32.07 (+0.31%) • MKT CAP: $4.02B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABCL VS. ARQT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABCL | ARQT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 90.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | -3.00% | -17.50 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.11% | -0.16% | -3.95 | ARQT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -3.30% | -56.70 | ARQT | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -4.30% | -55.70 | ARQT | /net-margins <GO> |
| Revenue Growth (YoY) | 160.60% | 91.30% | +69.30 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 7.78 | -1.18 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 65.6 | -16.65 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.00 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 24.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.24B | $4.02B | $218.3M | ABCL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABCL REV | ARQT REV | ABCL GROSS % | ARQT GROSS % | ABCL FCF | ARQT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.1M | $376.1M | — | 90.2% | -$174.1M | -$6.3M |
| FY 2024 | $28.8M | $196.5M | — | 90.3% | -$187.0M | -$112.3M |
| FY 2023 | $38.0M | $59.6M | — | — | -$43.9M | -$249.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABCL // BETA —
ARQT // BETA 1.00